The Manufacturers Life Insurance Company Acquires New Position in Twist Bioscience Corporation $TWST

The Manufacturers Life Insurance Company bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 79,848 shares of the company’s stock, valued at approximately $8,215,000. The Manufacturers Life Insurance Company owned approximately 0.13% of Twist Bioscience at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. ARK Investment Management LLC lifted its holdings in shares of Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after acquiring an additional 832,687 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after purchasing an additional 1,812,146 shares during the last quarter. BlackRock Inc. purchased a new position in Twist Bioscience in the 2nd quarter worth $600,191,000. EdgePoint Investment Group Inc. lifted its stake in Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after purchasing an additional 1,295,672 shares during the last quarter. Finally, State Street Corp lifted its stake in Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after purchasing an additional 538,755 shares during the last quarter.

Twist Bioscience Price Performance

NASDAQ TWST opened at $141.38 on Monday. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $155.44. The stock has a market capitalization of $8.87 billion, a PE ratio of -63.68 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The business’s 50-day moving average is $106.95 and its 200 day moving average is $74.01.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.33 EPS. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 41,570 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $151.98, for a total value of $6,317,808.60. Following the completion of the sale, the chief executive officer directly owned 770,729 shares of the company’s stock, valued at approximately $117,135,393.42. This trade represents a 5.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the sale, the insider directly owned 105,141 shares of the company’s stock, valued at approximately $9,436,404.75. This represents a 11.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 193,099 shares of company stock worth $24,026,581. 3.08% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently commented on TWST shares. Piper Sandler lifted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. UBS Group set a $89.00 target price on Twist Bioscience in a report on Monday, June 15th. Robert W. Baird raised their price target on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a research note on Monday, July 6th. Finally, Canaccord Genuity Group boosted their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.